Efficacy and safety of simoctocog alfa (Nuwiq®) in patients with severe hemophilia A: a review of clinical trial data from the GENA program

Simoctocog alfa (human-cl rhFVIII, Nuwiq®) is a 4th generation recombinant FVIII (rFVIII), without chemical modification or fusion with any other protein/fragment. Nuwiq® is produced in a human embryonic kidney cell line (HEK293F), which ensures human-specific post-translational protein processing....

Descripción completa

Detalles Bibliográficos
Autores principales: Lissitchkov, Toshko, Klukowska, Anna, Pasi, John, Kessler, Craig M., Klamroth, Robert, Liesner, Raina J., Belyanskaya, Larisa, Walter, Olaf, Knaub, Sigurd, Bichler, Johann, Jansen, Martina, Oldenburg, Johannes
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595650/
https://www.ncbi.nlm.nih.gov/pubmed/31263528
http://dx.doi.org/10.1177/2040620719858471

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6595650/
https://www.ncbi.nlm.nih.gov/pubmed/31263528
http://dx.doi.org/10.1177/2040620719858471

Ejemplares similares